Cart
sales@molnova.com
Home - Products - Others - Platelet aggregation - Rocepafant

Rocepafant

CAS No. 132579-32-9

Rocepafant( —— )

Catalog No. M34402 CAS No. 132579-32-9

Rocepafant (LAU8080) is a platelet-activating factor (PAF) antagonist that attenuates hypoxic-ischemic brain damage in neonatal rats.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 101 In Stock
10MG 148 In Stock
25MG 288 In Stock
50MG 384 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock
Get Quotation Bulk Inquiry Add to Cart

Biological Information

  • Product Name
    Rocepafant
  • Note
    Research use only, not for human use.
  • Brief Description
    Rocepafant (LAU8080) is a platelet-activating factor (PAF) antagonist that attenuates hypoxic-ischemic brain damage in neonatal rats.
  • Description
    Rocepafant (LAU8080) is a platelet-activating factor (PAF) antagonist that attenuates hypoxic-ischemic brain damage in neonatal rats.Rocepafant inhibits tumor necrosis factor-Afa-mediated cytotoxicity in mouse L929 tumor cells.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Platelet aggregation
  • Recptor
    Platelet aggregation
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    132579-32-9
  • Formula Weight
    535.08
  • Molecular Formula
    C26H23ClN6OS2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    CC=1N2C3=C(C4=C(S3)CN(C(NC5=CC=C(OC)C=C5)=S)CC4)C(=NCC2=NN1)C6=C(Cl)C=CC=C6
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog
related products

  • ENFENAMIC ACID

    Enfenamic acid is a platelet aggregation inhibitor and with antirheumatic.Dose-matched comparison between zinc-salt of enfenamic acid and the parent compound was carried out in experimentally wounded male albino rats bearing either sutured incision, dead-space or excision wounds.

  • SDZ-62-434

    SDZ-62-434, a platelet-activating factor inhibitor with antitumor activity, inhibits bombesin- and platelet-derived growth factor-induced DNA synthesis in quiescent Swiss 3T3 cells, making it a potential candidate for studying leukemia, human xenograft colorectal cancer, and lung cancer.

  • Etizolam

    Etizolam is a selective platelet-activating factor (PAF) antagonist.

Sign In Join Free